Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/04/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 19/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 19/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| -2.59% | -5.70% | +50.69% | +79.01% | 70.61B | |
| +3.23% | -10.67% | +6.27% | +53.48% | 51.01B | |
| +1.56% | +1.17% | +8.49% | +32.39% | 48.1B | |
| +0.39% | +0.65% | +31.14% | +27.04% | 42.78B | |
| +0.87% | -8.17% | +293.37% | +643.87% | 40.67B | |
| +1.24% | -1.01% | +10.74% | +94.55% | 40.3B | |
| -2.13% | -1.64% | +8.63% | +46.15% | 30.59B | |
| -1.30% | -4.06% | +47.39% | +7.05% | 28.16B | |
| +5.32% | +0.06% | -5.00% | -12.60% | 24.36B | |
| Average | +0.73% | -2.66% | +50.19% | +107.88% | 41.84B | |
| Weighted average by Cap. | +0.50% | -2.94% | +51.73% | +112.39% |
Employees
355
